Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials

2023210 citationsJournal Article

Authors

William F. McIntyre · Population Health Research Institute

Alexander P. Benz · Population Health Research Institute

Nina Becher · Ohio Heart & Vascular Center

Jeff S. Healey · Population Health Research Institute

Christopher B. Granger · Duke University

Léna Rivard · Montreal Heart Institute

A. John Camm

Abstract

The results of the NOAH-AFNET 6 and ARTESiA trials are consistent with each other. Meta-analysis of these 2 large randomized trials provides high-quality evidence that oral anticoagulation with edoxaban or apixaban reduces the risk of stroke in patients with device-detected atrial fibrillation and increases the risk of major bleeding.

Topics & Keywords

Atrial Fibrillation Management and Outcomes Cardiac Arrhythmias and Treatments Cardiac electrophysiology and arrhythmias

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Circulation

Volume 149, Issue 13, pp. 981-988

DOI: 10.1161/circulationaha.123.067512

Field-Weighted Citation Impact: 45.61